PODD

InsuletC

Nasdaq / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$180.00

Analysis reference price unavailable

Analysis 2026-09-10 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$160.00

Analysis reference price unavailable

Analysis 2026-09-10 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$115.00

Analysis reference price unavailable

Analysis 2026-09-10 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-10

AI commentary

Primary-source tone is operationally positive on broad-based growth, margin expansion, free cash flow, product launches, and pipeline data, but the outlook was reset lower for U.S. and total growth as type 2 scaling progresses. A secondary post-print review reported the stock down 11.6% since the earnings release and characterized next-quarter guidance as below consensus [#PR-EARNINGS-2026-09-04]. Social coverage and reliable post-print analyst revisions are unavailable, so the setup remains constructive but monitoring-oriented.

RankAlpha Sentiment Codex - 2026-09-10

Open full AI memo

Evidence flagged

report lacks a dated company-specific catalyst beyond generic cadence for its sector profile

Impact

tentative

Confidence

AI events

2026-12-09eventQ3 2026 guidance execution checkHigh impact

Insulet guided Q3 2026 total revenue growth of 17.5%-19.5% in constant currency, total Omnipod growth of 18%-20%, adjusted operating-margin expansion of approximately 100 bps, and adjusted EPS growth above 30%. Execution against this reset outlook is the clearest near-term catalyst. [#SEC-8K-2026-08-05]

2026-12-09catalystPost-earnings sentiment repairHigh impact

The stock is at $137.92 as of 2026-09-09, while the available analyst-target summary shows a median of $169.86; target count and post-print revisions are unavailable. A recovery would require investors to look past the lower U.S. and total-growth outlook.

2027-09-10catalystOmnipod ecosystem and automation expansionHigh impact

The company launched Omnipod 5 and Omnipod Discover in Spain, expanded sensor compatibility with Abbott FreeStyle Libre 3 Plus, and reported supportive Omnipod 6 and EVOLUTION 3 data. These support longer-term adoption, though commercialization timing is not disclosed. [#SEC-8K-2026-08-05]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-10 • Updated nightlySource: Internal modelMethodology